[HTML][HTML] Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
TC Westbrook, X Guan, E Rodansky, D Flores… - Nature …, 2022 - nature.com
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
TC Westbrook, X Guan, E Rodansky… - Nature …, 2022 - europepmc.org
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
TC Westbrook, X Guan, E Rodansky… - Nature …, 2022 - search.ebscohost.com
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
TC Westbrook, X Guan, E Rodansky… - Nature …, 2022 - escholarship.org
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
TC Westbrook, X Guan, E Rodansky… - Nature …, 2022 - econpapers.repec.org
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
TC Westbrook, X Guan, E Rodansky… - Nature …, 2022 - ui.adsabs.harvard.edu
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
TC Westbrook, X Guan, E Rodansky… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
TC Westbrook, X Guan, E Rodansky… - Nature …, 2022 - experts.umn.edu
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
TC Westbrook, X Guan, E Rodansky… - Nature …, 2022 - ohsu.elsevierpure.com
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
TC Westbrook, X Guan, E Rodansky… - Nature …, 2022 - ideas.repec.org
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …